Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies.

Lionaki S, Liapis G, Boletis JN.

Medicina (Kaunas). 2019 Jul 11;55(7). pii: E365. doi: 10.3390/medicina55070365. Review.

2.

Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients.

Stangou MJ, Marinaki S, Papachristou E, Liapis G, Pateinakis P, Gakiopoulou H, Nikolaidou C, Kolovou K, Lampropoulou IT, Zerbala S, Papadea P, Dounousi E, Balafa O, Pavlakou P, Andrikos A, Balassi E, Manolakaki P, Moustakas G, Galitsiou D, Mitsopoulos E, Vourlakou C, Choulitoudi V, Andronikidi PE, Stefanidis I, Golfinopoulos S, Dafnis E, Stylianou K, Panagoutsos S, Papadogianakis A, Tzanakis I, Sioulis A, Vlahakos D, Grapsa I, Tsilivigkou M, Kaperonis N, Paliouras C, Dioudis C, Spaia S, Apostolou T, Iatrou C, Boletis J, Goumenos D, Papagianni A.

Histopathology. 2019 Jul 18. doi: 10.1111/his.13955. [Epub ahead of print]

PMID:
31318463
3.

An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment.

Frangou E, Vassilopoulos D, Boletis J, Boumpas DT.

Autoimmun Rev. 2019 Aug;18(8):751-760. doi: 10.1016/j.autrev.2019.06.011. Epub 2019 Jun 8. Review.

PMID:
31181324
4.

Arterial Stiffness in Patients With Renal Transplantation; Associations With Co-morbid Conditions, Evolution, and Prognostic Importance for Cardiovascular and Renal Outcomes.

Korogiannou M, Xagas E, Marinaki S, Sarafidis P, Boletis JN.

Front Cardiovasc Med. 2019 May 24;6:67. doi: 10.3389/fcvm.2019.00067. eCollection 2019. Review.

5.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
6.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
7.

Impact of Primary Disease Nature in the Development of De Novo Donor-Specific Antibodies After Kidney Transplant and the Risk of Acute Rejection.

Lionaki S, Pappas A, Altanis N, Kapsia H, Liapis G, Vittoraki A, Iniotaki A, Zavos G, Boletis JN.

Exp Clin Transplant. 2019 Jun;17(3):304-312. doi: 10.6002/ect.2018.0054. Epub 2018 Oct 24.

8.

Celiac-like Enteropathy Associated With Mycophenolate Sodium in Renal Transplant Recipients.

Filiopoulos V, Sakellariou S, Papaxoinis K, Melexopoulou C, Marinaki S, Boletis JN, Delladetsima I.

Transplant Direct. 2018 Jul 20;4(8):e375. doi: 10.1097/TXD.0000000000000812. eCollection 2018 Aug.

9.

Coronary artery disease in renal transplant recipients: an angiographic study.

Paizis IA, Mantzouratou PD, Tzanis GS, Melexopoulou CA, Darema MN, Boletis JN, Barbetseas JD.

Hellenic J Cardiol. 2018 Jul 6. pii: S1109-9666(18)30101-5. doi: 10.1016/j.hjc.2018.07.002. [Epub ahead of print]

10.

The family of 14-3-3 proteins and specifically 14-3-3σ are up-regulated during the development of renal pathologies.

Rizou M, Frangou EA, Marineli F, Prakoura N, Zoidakis J, Gakiopoulou H, Liapis G, Kavvadas P, Chatziantoniou C, Makridakis M, Vlahou A, Boletis J, Vlahakos D, Goumenos D, Daphnis E, Iatrou C, Charonis AS.

J Cell Mol Med. 2018 Sep;22(9):4139-4149. doi: 10.1111/jcmm.13691. Epub 2018 Jun 28.

11.

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155/2018/7425785. eCollection 2018.

12.

IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.

Stangou M, Papasotiriou M, Xydakis D, Oikonomaki T, Marinaki S, Zerbala S, Stylianou C, Kalliakmani P, Andrikos A, Papadaki A, Balafa O, Golfinopoulos S, Visvardis G, Moustakas G, Papachristou E, Kouloukourgiotou T, Kapsia E, Panagiotou A, Koulousios C, Kavlakoudis C, Georgopoulou M, Panagoutsos S, Vlahakos DV, Apostolou T, Stefanidis I, Siamopoulos K, Tzanakis I, Papadogiannakis A, Daphnis E, Iatrou C, Boletis JN, Papagianni A, Goumenos DS.

Clin Kidney J. 2018 Feb;11(1):38-45. doi: 10.1093/ckj/sfx076. Epub 2017 Jul 31.

13.

Colchicine in Renal Diseases: Present and Future.

Marinaki S, Skalioti C, Boletis JN.

Curr Pharm Des. 2018;24(6):675-683. doi: 10.2174/1381612824666180123101313. Review.

PMID:
29359660
14.

Syndrome of Inappropriate Antidiuretic Hormone Secretion Complicating Systemic Nocardiosis in a Renal Transplant Recipient: A Case Report.

Melexopoulou C, Pavlopoulou ID, Zormpala A, Daikos GL, Boletis JN, Marinaki S.

Transplant Proc. 2017 Dec;49(10):2368-2371. doi: 10.1016/j.transproceed.2017.09.015.

PMID:
29198680
15.

Hepatitis B in renal transplant patients.

Marinaki S, Kolovou K, Sakellariou S, Boletis JN, Delladetsima IK.

World J Hepatol. 2017 Sep 8;9(25):1054-1063. doi: 10.4254/wjh.v9.i25.1054. Review.

16.

Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions.

Marinaki S, Skalioti C, Boletis J.

Transplant Proc. 2017 Mar;49(2):243-252. doi: 10.1016/j.transproceed.2016.11.035.

PMID:
28219579
17.

The clinical course of IgA nephropathy after kidney transplantation and its management.

Lionaki S, Panagiotellis K, Melexopoulou C, Boletis JN.

Transplant Rev (Orlando). 2017 Apr;31(2):106-114. doi: 10.1016/j.trre.2017.01.005. Epub 2017 Feb 2. Review.

PMID:
28209246
18.

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-center Experience.

Moris D, Kakavia K, Argyrou C, Garmpis N, Bokos J, Vernadakis S, Diles K, Sotirchos G, Boletis J, Zavos G.

Anticancer Res. 2017 Feb;37(2):773-779.

PMID:
28179329
19.

Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Lionaki S, Fragoulis GE, Venetsanopoulou A, Vlachoyiannopoulos P, Boletis JN, Tzioufas AG.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):155-164. Epub 2017 Jan 25.

PMID:
28134075
20.

A Heartbreaking Renal Transplantation: Is Norepinephrine the Culprit to Blame?

Vailas MG, Vernadakis S, Kakavia K, Paizis I, Bokos J, Boletis J, Zavos G.

Transplant Proc. 2016 Nov;48(9):3088-3091. doi: 10.1016/j.transproceed.2016.05.014.

PMID:
27932153
21.

Arteriovenous renal replacement therapy in end-stage left-sided heart failure patients has a detrimental effect on patients with impaired right ventricular function.

Repasos E, Kaldara E, Pantsios C, Kapelios C, Nana E, Vernadakis S, Melexopoulou C, Malliaras K, Boletis J, Nanas JN.

Hellenic J Cardiol. 2017 Jul - Aug;58(4):276-280. doi: 10.1016/j.hjc.2016.11.023. Epub 2016 Nov 23.

22.

The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries.

Lionaki S, Boletis JN.

Kidney Dis (Basel). 2016 Mar;1(4):224-34. doi: 10.1159/000442062. Epub 2015 Dec 5. Review.

23.

Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.

Lionaki S, Gakiopoulou H, Boletis JN.

APMIS. 2016 Sep;124(9):725-35. doi: 10.1111/apm.12566. Epub 2016 Jun 30. Review.

PMID:
27356907
24.

Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis.

Lionaki S, Mavragani CP, Karras A, Liapis G, Somarakis G, Boletis JN, Drosos A, Tzioufas AG, Guillevin L, Moutsopoulos HM.

J Autoimmun. 2016 Aug;72:57-64. doi: 10.1016/j.jaut.2016.05.004. Epub 2016 May 15.

PMID:
27194577
25.

ESRD patients in Greece during the financial crisis.

Naoum P, Kitsonis D, Topkaroglou I, Skroumpelos A, Athanasakis K, Melexopoulou C, Iatrou C, Boletis J, Kyriopoulos J.

Int J Artif Organs. 2016 Jul 4;39(5):258-9. doi: 10.5301/ijao.5000495. Epub 2016 May 2. No abstract available.

PMID:
27140296
26.

Organ donation during the financial crisis in Greece.

Moris D, Zavos G, Menoudakou G, Karampinis A, Boletis J.

Lancet. 2016 Apr 9;387(10027):1511-1512. doi: 10.1016/S0140-6736(16)30130-1. Epub 2016 Apr 7. No abstract available.

PMID:
27115977
27.

Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?

Filiopoulos V, Boletis JN.

World J Transplant. 2016 Mar 24;6(1):103-14. doi: 10.5500/wjt.v6.i1.103. Review.

28.

Cost calculations during "dire straits": a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece.

Naoum P, Topkaroglou I, Kitsonis D, Skroumpelos A, Athanasakis K, Iatrou C, Boletis J, Kyriopoulos J.

Int J Artif Organs. 2016 Feb;39(2):87-9. doi: 10.5301/ijao.5000477. Epub 2016 Mar 7.

PMID:
26953901
29.

Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: Experience of one center.

Melexopoulou C, Marinaki S, Liapis G, Skalioti C, Gavalaki M, Zavos G, Boletis JN.

World J Transplant. 2015 Dec 24;5(4):329-37. doi: 10.5500/wjt.v5.i4.329.

30.

Patients After Kidney Allograft Failure: Immunologic and Nonimmunologic Considerations.

Marinaki S, Skalioti C, Boletis J.

Transplant Proc. 2015 Nov;47(9):2677-82. doi: 10.1016/j.transproceed.2015.09.054. Review.

PMID:
26680071
31.

De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years.

Zavos G, Moris D, Kostakis ID, Vernadakis S, Bokos J, Zavvos V, Lionaki S, Boletis J.

Exp Clin Transplant. 2015 Aug;13(4):313-8.

32.

Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.

Skalioti C, Marinaki S, Darema M, Lionaki S, Antonakopoulos N, Zavos G, Boletis J.

Transplant Proc. 2015 Jul-Aug;47(6):1705-10. doi: 10.1016/j.transproceed.2015.05.029.

PMID:
26293038
33.

A Cytomegalovirus-related Pseudotumor in the Colon of A Renal Transplant Recipient Shrunk by Antiviral Therapy.

Lionaki S, Altanis N, Papaxoinis K, Delladetsima I, Daikos G, Boletis JN.

Transplantation. 2015 Jul;99(7):e46-7. doi: 10.1097/TP.0000000000000772. No abstract available.

PMID:
26147137
34.

The Importance of Novel Inflammatory Biomarkers in Renal Disease.

Marinaki S, Skalioti C, Siasos G, Papavassiliou AG, Tousoulis D, Boletis JN.

Curr Med Chem. 2015;22(23):2786-800. Review.

PMID:
25876748
35.

Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression.

Siasos G, Tsigkou V, Oikonomou E, Zaromitidou M, Tsalamandris S, Mourouzis K, Vavuranakis M, Anastasiou M, Vlasis K, Limperi M, Gennimata V, Boletis JN, Papavassiliou AG, Tousoulis D.

Curr Med Chem. 2015;22(22):2619-35. Review.

PMID:
25876747
36.

Hepatitis C in hemodialysis patients.

Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK.

World J Hepatol. 2015 Mar 27;7(3):548-58. doi: 10.4254/wjh.v7.i3.548. Review.

37.

Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience.

Lionaki S, Vlachopanos G, Georgalis A, Liapis G, Skalioti C, Zavos G, Boletis JN.

Ren Fail. 2015 Jun;37(5):777-83. doi: 10.3109/0886022X.2015.1015366. Epub 2015 Feb 26.

PMID:
25715638
38.

Clostridium difficile infection among kidney transplant recipients: frequency, clinical presentation, and outcome.

Lionaki S, Panagiotellis K, Moris D, Daikos G, Psyhogiou M, Vernadakis S, Zavos G, Boletis JN.

APMIS. 2015 Mar;123(3):234-9. doi: 10.1111/apm.12348. Epub 2014 Dec 31.

PMID:
25556694
39.

Exploring associations between anthropometric indices and graft function in patients receiving renal transplant.

Tsirigoti L, Kontogianni MD, Darema M, Iatridi V, Altanis N, Poulia KA, Zavos G, Boletis J.

J Hum Nutr Diet. 2016 Feb;29(1):52-8. doi: 10.1111/jhn.12289. Epub 2014 Dec 18.

PMID:
25522813
40.

Multicenter epidemiological study to assess the population of CKD patients in Greece: results from the PRESTAR study.

Sombolos K, Tsakiris D, Boletis J, Vlahakos D, Siamopoulos KC, Vargemezis V, Nikolaidis P, Iatrou C, Dafnis E, Xynos K, Argyropoulos C.

PLoS One. 2014 Nov 18;9(11):e112767. doi: 10.1371/journal.pone.0112767. eCollection 2014.

41.

Kidney transplantation in patients with systemic lupus erythematosus.

Lionaki S, Skalioti C, Boletis JN.

World J Transplant. 2014 Sep 24;4(3):176-82. doi: 10.5500/wjt.v4.i3.176. Review.

42.

Histological features of chronic hepatitis C in haemodialysis patients.

Sakellariou S, Boletis JN, Sypsa V, Psichogiou M, Tiniakos D, Delladetsima I.

Liver Int. 2014 Jul;34(6):e56-61. doi: 10.1111/liv.12413. Epub 2013 Dec 17.

PMID:
25234282
43.

Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.

Melexopoulou C, Marinaki S, Darema M, Skalioti C, Efthimiou A, Zavos G, Boletis JN.

Ren Fail. 2014 Jul;36(6):955-6. doi: 10.3109/0886022X.2014.900423. Epub 2014 Mar 26.

PMID:
24665854
44.

B cell depletion: rituximab in glomerular disease and transplantation.

Marinaki S, Skalioti C, Boletis JN.

Nephron Extra. 2013 Dec 31;3(1):125-30. doi: 10.1159/000356050. eCollection 2013 Jan. Review.

45.

Adenosine triphosphate production by peripheral blood CD4⁺T cells in clinically stable renal transplant recipients.

Vittoraki AG, Boletis JN, Darema MN, Kostakis AJ, Iniotaki AG.

Transplant Proc. 2014 Jan-Feb;46(1):108-14. doi: 10.1016/j.transproceed.2013.04.014.

PMID:
24507034
46.

Kidney transplantation outcomes from expanded criteria donors, standard criteria donors or living donors older than 60 years.

Lionaki S, Kapsia H, Makropoulos I, Metsini A, Skalioti C, Gakiopoulou H, Zavos G, Boletis JN.

Ren Fail. 2014 May;36(4):526-33. doi: 10.3109/0886022X.2013.876348. Epub 2014 Jan 23.

PMID:
24456131
47.

Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.

Lionaki S, Panagiotellis K, Iniotaki A, Boletis JN.

Clin Dev Immunol. 2013;2013:849835. doi: 10.1155/2013/849835. Epub 2013 Nov 21. Review.

48.

Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.

Arnold ML, Ntokou IS, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG.

Transpl Int. 2014 Mar;27(3):253-61. doi: 10.1111/tri.12206. Epub 2013 Oct 31.

49.

Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis.

Liapis G, Boletis J, Skalioti C, Bamias G, Tsimaratou K, Patsouris E, Delladetsima I.

Histopathology. 2013 Nov;63(5):649-58. doi: 10.1111/his.12222. Epub 2013 Sep 11.

PMID:
24025088
50.

Clinical evaluation of the endothelial tie-2 crossmatch in ABO compatible and ABO incompatible renal transplants.

Kafetzi ML, Boletis JN, Melexopoulou CA, Tsakris A, Iniotaki AG, Doxiadis II.

Hum Immunol. 2013 Nov;74(11):1425-30. doi: 10.1016/j.humimm.2013.06.003. Epub 2013 Jun 18.

PMID:
23792052

Supplemental Content

Loading ...
Support Center